Selentra HP

Calroy Health Sciences Selentra HP Menopause & Perimenopause Support Selentra HP™, powered by FEM-936™, supports women’s mid-life health. Selentra HP supports the biological foundation of the menopause transition, backed by research and formulated for what comes next. Key Benefits and Features:  Supports a healthy inflammatory response during menopause Supports metabolic resilience during hormonal change Supports a healthy gut Helps maintain healthy bone density and structure Ingredients  Serving Size: 2 Capsules Amount/Serving Proprietary FEM-936 Blend containing:  1,100 mg  OsteoCaf Indian Rosewood (Dalbergia sissoo) leaf extract  600 mg  VMK2223 (Bifidobacterium breve BB091109 Postbiotic Extract)  500 mg  Other Ingredients: Vegan Capsule (Hypromellose), Rice Bran Extract, Rice Hull Concentrate.  Vegan  Suggested Use Take 1 capsule twice daily.  Warning: Keep out of the reach of children.  Storage: Keep tightly closed in a cool, dry place.  More Info. The Effects The new blueprint for women’s longevity. The menopause transition is long, complex, and different for every woman. Symptoms come and go and change over time. Hot flashes for one woman, disrupted sleep, or a shift in inflammatory balance for another. What's consistent is the underlying process: estrogen decline impacts gut barrier function, bone and immune health, and hormonal regulation – long before symptoms make them visible. Most approaches address symptoms one at a time as they appear. Selentra HP supports the underlying system: the gut-hormone-bone axis through which estrogen decline makes its widest impact. It's formulated with two clinically studied, patented ingredients built specifically for this transition. Selentra HP is hormone-free and appropriate whether or not you're using menopausal hormone therapy, so you don't have to choose between the two. This is a critical inflection point where many women's health trajectories change. The science is clear, the support is not: menopause is understudied, under-treated, and under-discussed, and most care addresses symptoms rather than root cause. We can change that by treating the underlying biology. The Science Beyond Hormones. Beyond Symptoms. Women are underserved during the menopausal transition. Too many formulas aim to manage symptoms one at a time, rather than addressing the systems underneath them. Selentra HP targets the biological system that governs hormonal regulation, inflammatory balance, and skeletal health simultaneously during this transition. It’s foundational support.  As hormones change during menopause, a self-reinforcing cycle emerges: estrogen decline affects gut barrier permeability, immune balance shifts, and hormone and bone health are impacted. Three systems, one cascade, one originating event. The impacts aren’t contained in the gut. The whole body feels this change, and foundational support can make a difference. The Research Clinically Validated. Peer-Reviewed. Trusted by Experts. Selentra HP is powered by two clinically studied, patented ingredients, each supported by published, peer-reviewed clinical studies conducted in peri- and postmenopausal women, the population this formula was designed for. In a 12-week, randomized, placebo-controlled trial of women ages 40–55, VMK223 was associated with measurable reductions in key inflammatory markers, including CRP and IL-6, two standard measures of systemic inflammation. These findings are consistent with support for a healthy inflammatory response during menopause, alongside improvements in the secondary endocrine markers cortisol and DHEA. A separate published trial in the same population found measurable improvements in skin hydration (+28%), elasticity (+27%), and wrinkle depth (−28%) over 12 weeks, outcomes researchers connect to the same gut-barrier and immune pathway. In a one-year clinical study, postmenopausal women taking OsteoCaf at 600 mg daily, the same dose used in Selentra HP, maintained stable bone mineral density at the majority of measured sites. Ingredients Thoughtfully sourced, quality controlled, vegan  Selentra HP™ is powered by FEM-936™, a new proprietary blend of two clinically studied, patented ingredients formulated to support this connected system. VMK223™ is a postbiotic, a newer class of gut-health ingredient that works differently from probiotics or prebiotics. Rather than introducing live bacteria, VMK223 delivers the beneficial compounds bacteria produce directly. Postbiotics don't depend on the microbiome to work; they deliver the benefits directly. VMK223 engages two key immune receptors: one that calms gut-driven immune responses, and one that strengthens the gut barrier itself. That makes it predictable by design. Unlike probiotics, whose effects vary with each woman's existing microbiome, VMK223 works at the receptor level, so it behaves consistently regardless of a woman's individual gut makeup. OsteoCaf™ is a patented extract of Dalbergia sissoo (Indian rosewood). Bone is living tissue, constantly being broken down and rebuilt. OsteoCaf promotes bone-building activity during the menopausal transition. It does this without hormonal activity, making it appropriate for any woman regardless of her history with hormone therapy. Every batch of Selentra HP is produced under Calroy's Total Quality System, with strict compliance to FDA-defined current Good Manufacturing Practices (cGMP). Batch and test records are maintained to ensure guaranteed purity, potency, and quality.